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OBJECTIVE — We investigated stroke mortality in individuals in different categories of
glycemia and compared hazard ratios (HRs) corresponding to a 1-SD increase in 2-h plasma
glucose and fasting plasma glucose (FPG) criteria.
RESEARCH DESIGN AND METHODS — We examined data from 2-h 75-g oral glu-
cose tolerance tests taken from 13 European cohorts comprising 11,844 (55%) men and 9,862
(45%) women who were followed up for a median of 10.5 years. A multivariate adjusted Cox
proportional hazards model was used to estimate HRs for stroke mortality.
RESULTS — In men and women without a prior history of diabetes, multivariate adjusted
HRsforstrokemortalitycorrespondingtoa1-SDincreaseinFPGwere1.02(95%CI0.83–1.25)
and 1.52 (1.22–1.88) and those in 2-h plasma glucose 1.21 (1.06–1.38) and 1.31 (1.06–1.61),
respectively. Addition of 2-h plasma glucose to the model with FPG signiﬁcantly improved
predictionofstrokemortalityinmen(
210.12;P0.001)butnotinwomen(
20.01;P
0.94), whereas addition of FPG to 2-h plasma glucose improved stroke mortality in women
(
2  4.08; P  0.04) but not in men (
2  3.29; P  0.07).
CONCLUSIONS — Diabetes deﬁned by either FPG or 2-h plasma glucose increases the risk
of stroke mortality. In individuals without a history of diabetes, elevated 2-h postchallenge
glucoseisabetterpredictorthanelevatedfastingglucoseinmen,whereasthelatterisbetterthan
the former in women.
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S
everal epidemiological studies have
indicated that diabetes is a major
risk factor for stroke (1) and stroke
recurrence (2). Some studies have also
found an increased incidence of stroke
withelevatedbloodglucoselevelsinnon-
diabetic individuals (3,4). Yet, not all
studies have conﬁrmed these ﬁndings
(5,6) or have found a similar association
only in women (7). Recently, a systematic
overview of epidemiological studies and
surveysfrom52countriesfoundthat13%
of stroke mortality cases were associated
with elevated blood glucose levels mea-
sured by fasting plasma glucose (FPG)
levels(4).Theassociationbetweenhyper-
glycemia and stroke events is, however,
notasunequivocallydescribedasthatbe-
tween hyperglycemia and coronary heart
disease (CHD). The Diabetes Epidemiol-
ogy: Collaborative analysis Of Diagnostic
criteria in Europe (DECODE) Study
Group revealed that 2-h postchallenge
hyperglycemia is more strongly related to
CHD than fasting hyperglycemia. A simi-
lar correlation was, however, not found
for stroke mortality, probably because of
the low number of stroke events (8).
With an extended the follow-up and
an increase in the number of participants,
the number of stroke events have accu-
mulated in the DECODE study. We have
therefore now reexamined the relation-
ship between hyperglycemia and stroke
mortality and compared the difference
between the 2-h and the fasting glucose
criteria in prediction of stroke mortality.
RESEARCH DESIGN AND
METHODS— The study population
comprised 21,706 individuals, 11,844
(55%) men and 9,862 (45%) women,
from 13 European cohorts. The age range
at the baseline survey was 25–90 years
with mean ages varying from 45 to 76
years in different cohorts. The maximum
duration of follow-up ranged from 3.8 to
27.9 years among different cohorts with a
median follow-up of 10.5 years. Among
the study population, 1,196 (5.5%) indi-
viduals had previously been diagnosed
withdiabetes.Individualswhohadprevi-
ouslynotbeendiagnosedasdiabeticwere
classiﬁed according to either 2-h plasma
glucose criteria (11.1 mmol/l for diabe-
tes, 7.8–11.0 mmol/l for impaired glu-
cose tolerance [IGT], and 7.8 mmol/l
for normal glucose tolerance [NGT]) or
FPG criteria (7.0 mmol/l for diabetes,
6.1–6.9 mmol/l for impaired fasting glu-
cose [IFG], and 6.1 mmol/l for normal
fastingglucose[NFG]).Measurementsfor
2-h plasma glucose, FPG, BMI, total se-
rum cholesterol, systolic and diastolic
blood pressure, antihypertensive treat-
ment, and smoking status were available
for each study population included in the
current analysis.
Vital status and the cause of death
wererecordedforparticipantsinallofthe
studies. Participants who had emigrated
and whose vital status could not be con-
ﬁrmedweretreatedascensoredcases.Ce-
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point and coded according to the ICD
with codes 430–438 (8th and 9th revi-
sions)andcodesI60–I69(10threvision).
The methods to recruit participants for
the DECODE cohorts have been de-
scribed previously (8,9). Brieﬂy, the data-
base was collected from researchers who
had performed epidemiological studies
using standard 2-h 75-g oral glucose tol-
erance tests in Europe. Individual data
from different participating European co-
horts were sent to the Diabetes and Ge-
netic Epidemiology Unit of the National
Public Health Institute in Helsinki, Fin-
land, for data analyses. Each study had
been approved by the local ethics com-
mittees, and the ethics committee of the
NationalPublicHealthInstituteapproved
the data analysis plan.
Statistical methods
A general linear model of univariate
ANOVA was used to estimate the means
adjusted for age and center. The Cox pro-
portional hazards model was used to cal-
culate hazard ratios (HRs) and their 95%
CIs for stroke mortality in the different
FPG and 2-h plasma glucose levels. The
models were adjusted for age, center, hy-
pertension status (140/90 mmHg or
treatment), BMI, total serum cholesterol,
smoking status, and sex. BMI was calcu-
lated as weight in kilograms divided by
height in meters squared, and smoking
status was classiﬁed as current smoker,
exsmoker, or nonsmoker. Cumulative
mortality curves were plotted using the
same multivariate Cox proportional haz-
ards analysis. 
2 log-likelihood ratio tests
were used to determine the difference be-
tween the FPG and 2-h plasma glucose
criteria. SPSS (version 15; SPSS, Chicago,
IL) was used for data analysis.
RESULTS— The number of partici-
pants,theirdemographicdataatbaseline,
and the number of stroke events in each
DECODE cohort that accumulated dur-
ing the follow-up years are shown in Ta-
ble 1. Mortality from stroke was higher in
diabetic than in nondiabetic individuals.
Individuals previously not diagnosed as
diabetic with 2-h plasma glucose levels
11.1mmol/lorFPGlevels7.0mmol/l
were older and had higher BMI and cho-
lesterol levels than individuals with 2-h
plasma glucose 11.1 mmol/l or FPG
7.0 mmol/l. Similar results were found
in both men and women (Table 2).
The multivariate-adjusted HR for fa-
tal stroke events was highest in men with
screen-detected diabetes deﬁned by 2-h
plasma glucose criteria as compared with
men with NGT or IGT. A signiﬁcant in-
crease in HRs was seen in women with
screen-detected diabetes deﬁned by ei-
ther FPG or 2-h plasma glucose criteria as
comparedwithwomenwithNFGorNGT
(Table 2). The cumulative hazards were
highest in people with previously diag-
nosed diabetes and screen-detected dia-
betes deﬁned by both criteria (Fig. 1A–B
and Fig. 2A–B); the risk was moderately
increased for IFG in women (Fig. 1B) and
for IGT in men (Fig. 2A). The risk of fatal
stroke events was lowest in men with
NFG or IFG (Fig. 1A) and in women with
NGT or IGT (Fig. 2B). Thus, the classiﬁ-
cationbasedon2-hplasmaglucosebetter
discriminated fatal stroke events in men,
whereas that based on FPG was a better
predictor in women.
The HRs corresponding to a 1-SD in-
crease in 2-h plasma glucose or FPG are
showninTable3.Thelog-likelihoodratio
test showed that addition of 2-h plasma
glucose to the model with FPG signiﬁ-
cantly improved the prediction of the
model (
2  10.45; P  0.001) in all
individuals and in men (
2  10.12; P 
0.001)butnotinwomen(
20.01;P
0.94). Addition of FPG to the model with
2-h plasma glucose improved the predic-
tion of stroke mortality in women but not
in men (Table 3). Interaction of sex with
FPG was found to be signiﬁcant (P 
0.05) but not with 2-h plasma glucose
(P  0.53).
Becausewaistcircumferenceandtrig-
lycerideswerenotmeasuredinallcohorts
includedinthecurrentdataanalysis,they
were not adjusted in the ﬁnal model.
Their effects were, however, tested in a
subgroup of 9,010 (42%) men and 8,900
(41%)womenwithmeasurementofwaist
andasubgroupof10,379(48%)menand
8,235 (38%) women with triglycerides.
Adjustment for either waist or triglycer-
ides did not change the results for 2-h
plasma glucose in men or FPG in women,
but it attenuated the hazards for 2-h
plasma glucose in women and FPG in
men. The HRs adjusting for waist corre-
spondingtoa1-SDincreasein2-hplasma
glucosewere1.23(95%CI0.99–1.52)in
men and 1.07 (0.78–1.48) in women;
those corresponding to a 1-SD increase in
FPG were 1.08 (0.86–1.35) in men and
1.38 (0.95–2.00) in women. HRs adjust-
Table 1—Demographic data at baseline and number of stroke events during the follow-up in each study
Men Women Age (years)
Stroke Maximum
follow-up years Men Women
Finland, East-West* 405 — 76.2  4.5 29 (7.2) — 16.2
FINRISK-1987 1,261 1,440 54.0  5.8 25 (2.0) 24 (1.7) 19.0
FINRISK-1992 877 1,041 54.1  6.0 6 (0.7) 7 (0.7) 14.0
FINRISK-2002 1,786 2,055 57.9  7.8 3 (0.2) 2 (1.2) 3.9
Helsinki Policemen Study* 1,136 — 44.7  8.0 79 (7.0) — 36.8
Vantaa 271 335 65.2  0.4 5 (1.8) 9 (2.7) 13.9
Italy, Cremona 799 1,003 58.4  10.8 5 (0.6) 2 (0.2) 6.9
The Netherlands, Hoorn Study 1,087 1,282 61.7  7.3 12 (1.1) 11 (0.9) 10.2
Zuthpen Study* 479 — 75.8  4.5 9 (1.9) — 4.8
Sweden, MONICA 1,733 1,760 48.9  13.4 18 (1.0) 8 (0.5) 20.6
Uppsala* 1,164 — 71.0  0.6 27 (2.3) — 12.4
U.K., Goodinge 448 570 54.6  10.3 8 (1.8) 1 (0.2) 9.7
Newcastle 398 376 54.8  12.5 5 (1.3) 4 (1.1) 10.6
Total 11,844 9,862 56.8  11.3 231 (2.0) 68 (0.7) 36.8
Data are n, means  SD, or n (%), unless otherwise indicated. *The study includes only men.
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glucose 1.24 (1.03–1.50) in men and
0.98 (0.65–1.49) in women, whereas for
FPG 0.87 (0.69–1.10) and 1.50 (0.90–
2.48), respectively. Further adjustment
foreitherwaistortriglyceridesinthesub-
groups did not change the main results
based on the whole study population.
CONCLUSIONS — We conﬁrmed in
this analysis that diabetes deﬁned by ei-
ther FPG or 2-h plasma glucose criteria
conveyed increased stroke mortality. In-
dividuals with IFG deﬁned according to
the FPG criteria alone had a stroke mor-
tality lower than those with diabetes but
higher than those with NFG in women
but not in men, whereas the opposite was
found for IGT and NGT. Stroke mortality
was higher in men with IGT than in men
with NGT, but such a difference was not
seen in women.
Overt diabetes (1,10) as well as dia-
betes deﬁned based on 1-h postload glu-
cose (11), FPG levels (12,13), or
nonfasting glucose levels (7,14) have
been reported to predict an increased risk
of stroke. Yet, studies that have con-
ducted a 2-h oral glucose tolerance test
and compared the stroke risk between
2-h postload hyperglycemia and fasting
hyperglycemia are rare. Moreover, be-
cause the category IFG has only recently
been introduced (15), studies estimating
the stroke risk in individuals with IFG
compared with those with IGT are very
few. The DECODE Study Group (8) pre-
viouslyfoundthattheriskofstrokedeath
was higher in women with IFG than with
IGT (8), but as a result of the low number
of stroke deaths, a direct comparison be-
tween FPG and 2-h plasma glucose was
not made separately for men and women.
With the increasing number of stroke
deaths accumulated in the DECODE co-
horts,theglucose-strokerelationshipwas
reinvestigatedindetailinthepresentdata
analysis. With regard to CHD mortality,
Table 2—Baseline characteristics and multivariate adjusted HR (95% CI) for death from stroke for subjects according to FPG and 2-h plasma
glucose categories
FPG 2-h plasma glucose
Known diabetes 6.1 6.1–6.9 7.0 7.8 7.8–11.0 11.1
Men
n (%) 8,540 (72.1) 2,043 (17.2) 537 (4.5) 9,065 (76.5) 1,558 (13.2) 497 (4.2) 724 (6.1)
Age (years) 56.9  0.1 57.2  0.3 62.4  0.5 55.8  0.1 63.2  0.3 65.1  0.5 62.8  0.4
BMI (kg/m
2) 26.3  0.0 27.4  0.1 29.0  0.2 26.3  0.0 27.7  0.1 28.9  0.2 28.3  0.1
Cholesterol (mmol/l) 6.04  0.01 6.09  0.03 6.11  0.05 6.07  0.01 5.99  0.03 6.04  0.05 5.78  0.04
SBP (mmHg) 140  0.2 145  0.4 148  0.9 140  0.2 147  0.5 151  0.9 145  0.7
DBP (mmHg) 83  0.1 85  0.3 87  0.5 83  0.1 86  0.3 87  0.5 84  0.4
Smoking 2,507 (29.4) 637 (31.2) 157 (29.2) 2,835 (31.3) 360 (23.1) 106 (21.3) 166 (22.9)
Stroke
n (%) 141 (1.7) 45 (2.2) 15 (2.8) 153 (1.7) 35 (2.2) 13 (2.6) 30 (4.1)
n per 1,000
person-years 1.46 1.90 3.24 1.43 2.47 3.50 5.57
HR (95% CI) 1 1.05 (0.74–1.49) 1.37 (0.79–2.38) 1 1.43 (0.97–2.11) 1.82 (1.01–3.29) 3.32 (2.16–5.12)
Women
n (%) 8,169 (82.8) 969 (9.8) 252 (2.6) 7,766 (78.7) 1,281 (13.0) 343 (3.5) 472 (4.8)
Age (years) 54.9  0.1 59.0  0.3 61.1  0.6 54.5  0.1 59.6  0.3 62.4  0.5 60.8  0.5
BMI (kg/m
2) 26.5  0.1 28.6  0.2 30.6  0.3 26.4  0.1 28.6  0.1 30.0  0.3 30.1  0.2
Cholesterol (mmol/l) 6.22  0.01 6.27  0.04 6.32  0.07 6.22  0.01 6.27  0.03 6.21  0.06 5.86  0.05
SBP (mmHg) 137  0.2 141  0.7 143  1.3 137  0.2 144  0.6 147  1.1 147  1.0
DBP (mmHg) 80  0.1 81  0.4 82  0.7 80  0.1 83  0.3 84  0.6 81  0.5
Smoking 1,650 (20.2) 237 (24.5) 67 (26.6) 1,712 (22.0) 184 (14.4) 58 (16.9) 67 (14.2)
Stroke
n (%) 37 (0.5) 10 (1.0) 7 (2.8) 36 (0.5) 9 (0.7) 9 (2.6) 14 (3.0)
n per 1,000
person-years 0.44 1.25 3.35 0.46 0.72 3.03 3.93
HR (95% CI) 1 2.04 (0.99–4.21) 4.73 (2.00–11.18) 1 0.90 (0.43–1.90) 3.33 (1.55–7.14) 5.60 (2.86–10.96)
Total
n (%) 16,709 (77.0) 3,012 (13.9) 789 (3.6) 16,831 (77.5) 2,839 (13.1) 840 (3.9) 1,196 (5.5)
Age (years) 56.0  0.1 57.6  0.2 61.8  0.4 55.2  0.1 61.6  0.2 63.9  0.4 61.9  0.3
BMI (kg/m
2) 26.4  0.0 27.9  0.1 29.5  0.1 26.4  0.0 28.1  0.1 29.3  0.1 29.1  0.1
Cholesterol (mmol/l) 6.12  0.01 6.20  0.02 6.20  0.04 6.14  0.01 6.11  0.02 6.12  0.04 5.83  0.03
SBP (mmHg) 139  0.2 144  0.4 146  0.7 138  0.2 145  0.4 149  0.7 146  0.6
DBP (mmHg) 82  0.1 83  0.2 85  0.4 82  0.1 85  0.2 86  0.4 82  0.3
Smoking 4,157 (24.9) 874 (29.0) 224 (28.4) 4547 (27) 544 (19.2) 164 (19.5) 233 (19.5)
Stroke
n (%) 178 (1.1) 55 (1.8) 22 (2.8) 189 (1.1) 44 (1.5) 22 (2.6) 44 (3.7)
n per 1,000
person-years 0.98 1.74 3.27 1.02 1.65 3.29 4.92
HR (95% CI) 1 1.19 (0.87–1.64) 1.83 (1.16–2.89) 1 1.30 (0.92–1.84) 2.31 (1.46–3.67) 3.85 (2.68–5.53)
Dataaren(%)andmeansSEunlessotherwiseindicated.Dataareadjustedforage,study,andsex(whenmenandwomencombined).FPGand2-hplasmaglucose
criteria are in mmol/l. DBP, diastolic blood pressure; SBP, systolic blood pressure.
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women together, the ﬁndings of the
present study (results not shown) were in
accordance with the previous ﬁndings
(8). Also, in the present study, when men
and women were pooled, the 2-h plasma
glucose–stroke relation was still stronger
than the FPG-stroke relation. However,
when the data were analyzed separately,
Figure 1—Cumulative stroke mortality curves derived from Cox regression analysis for FPG (mmol/l) and for people with prior history of diabetes
(known DM) in men (A) and in women (B). The analysis is adjusted for age, study, BMI, total cholesterol, smoking, and hypertension status.
Hyva ¨rinen and Associates
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cose criteria better predicted stroke mor-
tality than the FPG criteria, but in women
the role was reversed. When the data are
analyzed with men and women together,
the majority of the stroke deaths come
from men, and the results of the men
drive the direction of the analysis; thus,
thesexdifferencesinFPGand2-hplasma
Figure 2—Cumulative stroke mortality curves derived from Cox regression analysis for 2-h plasma glucose (mmol/l) and for people with prior
history of diabetes (known DM) in men (A) and in women (B). The analysis is adjusted for age, study, BMI, total cholesterol, smoking, and
hypertension status.
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remain undetected.
Diabetes increases the risk of CHD
events (16).The risk is more markedly in-
creased in diabetic women than in dia-
beticmen(17).Thiswasalsofoundinthe
current study population of all ages: the
ratio of male CHD mortality to female
CHD mortality in subjects with normal
glucose levels (both NFG and NGT) and
with diabetes (diagnosed or undiag-
nosed) was 5.94 and 2.53, respectively.
The underlying pathophysiologies of
IFGandIGTaredifferent.IFGispredom-
inantly associated with hepatic insulin re-
sistance and decreased ﬁrst-phase insulin
secretion, whereas IGT is associated with
peripheral insulin resistance and impair-
mentofbothearly-andlate-phaseinsulin
responses (18). A population study in
Mauritius reported that men have lower
levels of -cell function and higher prev-
alence of IFG than women and women
have lower insulin sensitivity and higher
prevalence of IGT than men (19). Thus,
the stroke mortality in relation to the two
glucose categories may also differ be-
tween the two sexes, which could partly
explain the differences found between
men and women in the present study.
Abdominal adiposity, measured as
waist circumference or as waist-to-hip ra-
tio, has been found to increase the risk of
ischemic stroke in both men and women
(20) or in men only (21). Plasma triglyc-
eride levels have also been shown to have
an association with increased risk of
stroke in some (22) but not all studies
(23) or have been found to have an in-
creased stroke risk only in women (24).
Because the two variables, waist circum-
ference and triglycerides, were not mea-
sured in all of the cohorts used in the
present study, adjustments for these vari-
ables were not done in the ﬁnal data anal-
ysis. However, when their effect was
tested in a subgroup of individuals, the
results did not change, indicating that
the2-hplasmaglucosecategoryimproves
the prediction of stroke mortality in men
compared with FPG category alone,
whereasthelatterisbetterthantheformer
in women.
Overt diabetes is more closely related
to ischemic stroke than to hemorrhagic
stroke (25). Regardless of the relatively
large sample size, the follow-up duration
for many of the cohorts in the present
study is still short, with few stroke events
accumulated, and as a result of the small
number of stroke events in women, we
couldnotfurtherclassifypeopleintoisch-
emicorhemorrhagicstroke.Thisisoneof
thelimitationsofthecurrentstudy.Inad-
dition, in the DECODE study, some co-
horts included men only, and thus
cohorts for men and women in the
present analysis were to some extent dif-
ferent. One may speculate that the sex-
speciﬁc glucose-stroke relationship is
study-dependent. However, when we
limit the data analysis to the studies com-
prising both men and women, the results
were not changed. The strength of the
present study is that all the cohorts used
in the study had data available for both
FPG and 2-h glucose levels. This is the
ﬁrst study to investigate the question of
glucose levels and the risk of stroke in a
study group where all participants had a
2-h 75-g oral glucose tolerance test. The
collaborative data analysis gives more sta-
tisticalpowerthaniftheanalysishadbeen
performed individually by the different
centers, and thus avoids the spurious re-
sults caused by a small study. To try to
take into account the difference between
studies, in all pooled data analysis, “co-
hort” was adjusted for.
In summary, the present study con-
ﬁrmed that diabetes deﬁned by either
fasting or postchallenge criteria is a pre-
dictorofstrokemortalityinbothsexes.In
people without diabetes, elevated 2-h
postchallengeglucoseisabetterpredictor
than elevated fasting glucose in men,
whereas fasting plasma glucose is better
than 2-h postchallenge glucose in
women.
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2-h plasma glucose 1.23 (1.08–1.40) 1.34 (1.09–1.65) 1.18 (1.03–1.36)
Model 3† Model 2  hypertension
FPG 1.02 (0.83–1.25) 1.52 (1.22–1.88) 1.16 (1.00–1.33)
2-h plasma glucose 1.21 (1.06–1.38) 1.31 (1.06–1.61) 1.25 (1.12–1.40)

2 for FPG, 1 df (P) 3.29 (0.07) 4.08 (0.04) 0.57 (0.45)

2 for 2-h PG, 1 df (P) 10.12 (0.001) 0.01 (0.94) 10.45 (0.001)

2 indicates the changes in the model prediction when FPG or 2-hPG was removed from the model where both were ﬁtted simultaneously. Subjects with diagnosed
diabetes were excluded. *Adjusted for sex when men and women are combined. †SD  1.3 for FPG and SD  2.7 for 2-h plasma glucose.
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